Bank of America upgraded shares of Mylan (NASDAQ:MYL) from a neutral rating to a buy rating in a research report released on Tuesday, Marketbeat.com reports. The firm currently has $42.00 target price on the stock, down from their prior target price of $44.00.

A number of other brokerages have also issued reports on MYL. Cowen reiterated a hold rating and set a $31.00 price target on shares of Mylan in a research report on Thursday, August 9th. Wells Fargo & Co reiterated a hold rating on shares of Mylan in a research report on Wednesday, July 25th. ValuEngine upgraded Mylan from a sell rating to a hold rating in a research report on Tuesday, August 14th. Mizuho lowered Mylan from a buy rating to a neutral rating in a research report on Friday, October 5th. Finally, Leerink Swann reduced their price target on Mylan from $53.00 to $47.00 and set an outperform rating for the company in a research report on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. Mylan presently has a consensus rating of Buy and an average target price of $46.87.

MYL traded down $0.20 during trading on Tuesday, reaching $36.95. 4,300,237 shares of the company were exchanged, compared to its average volume of 6,462,479. The company has a market cap of $18.84 billion, a P/E ratio of 8.10, a PEG ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77. Mylan has a 52 week low of $30.33 and a 52 week high of $47.82.

Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 5th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.19 by $0.06. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the previous year, the firm posted $1.10 EPS. The firm’s quarterly revenue was down 4.2% on a year-over-year basis. As a group, research analysts anticipate that Mylan will post 4.68 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in MYL. First Mercantile Trust Co. acquired a new stake in shares of Mylan in the second quarter valued at $121,000. Stratos Wealth Partners LTD. acquired a new stake in shares of Mylan in the third quarter valued at $183,000. CENTRAL TRUST Co lifted its holdings in shares of Mylan by 1,057.8% during the second quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock valued at $188,000 after purchasing an additional 4,760 shares during the last quarter. FTB Advisors Inc. purchased a new stake in shares of Mylan during the second quarter valued at $188,000. Finally, Reilly Financial Advisors LLC lifted its holdings in shares of Mylan by 69.4% during the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock valued at $191,000 after purchasing an additional 2,137 shares during the last quarter. Institutional investors and hedge funds own 82.99% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Featured Article: Why do companies issue stock splits?

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.